Source: International Congress 2015 – IPF: clinical aspects
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Miia Kärkkäinen (Kuopio, Finland), Miia Kärkkäinen, Hannu-Pekka Kettunen, Hanna Nurmi, Minna Purokivi, Riitta Kaarteenaho. Course of disease and cause of death in patients with idiopathic pulmonary fibrosis in Eastern Finland. Eur Respir J 2015; 46: Suppl. 59, 2044

Member's Comments

No comment yet.

Related content which might interest you: Tuberculosis in patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Accuracy of “pulmonary fibrosis” diagnosis on death certificates – All scarring isn’t IPF Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 A prothrombotic state is associated with increased mortality in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Registry of idiopathic pulmonary fibrosis patients Source: International Congress 2016 – Russia Session Year: 2016 Disease progression in early idiopathic pulmonary fibrosis: Insights from the Australian IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Interstitial lung diseases in childhood Source: ISSN=1025-448x, ISBN=1-904097-22-7, page=213 Year: 2002 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Prognostic significance of selected biomarkers in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease Source: International Congress 2014 – Sarcoidosis Year: 2014 Idiopathic pulmonary fibrosis: a treatable disease? Source: Eur Respir J 2003 Dec 01;22(6):872-873 Year: 2003 Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Predictors of death or transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016